Seneca Biopharma Granted 180-Day Extension by NASDAQ to Regain Compliance with Bid Price Rule
Seneca Biopharma, Inc. (Nasdaq: SNCA) announced on December 15, 2020, that it received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share. This extension gives the company until June 9, 2021, to meet the requirement by maintaining the closing bid price at or above the threshold for at least ten consecutive business days. If compliance is not achieved, Seneca could face delisting but has the option to appeal the decision.
- Received a 180-day extension from Nasdaq to meet bid price requirement.
- New compliance deadline set for June 9, 2021.
- Failure to regain compliance could lead to delisting from Nasdaq.
GERMANTOWN, Md., Dec. 15, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced that it has received written notification from The Nasdaq Stock Market ("Nasdaq") dated December 11, 2020 that it has granted the company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company now has until June 9, 2021 to meet the bid price requirement.
The company can cure this deficiency if the closing bid price of its common stock is
About Seneca Biopharma, Inc.
Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need. The Company is in the process of transforming the organization through the acquisition or in-licensing of new science and technologies, to develop with the goal of providing meaningful therapies for patients.
Cautionary Statement Regarding Forward Looking Information:
This news release contains "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "seek" or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Seneca's periodic reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Reports on Form 10-Q as well as and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.
View original content:http://www.prnewswire.com/news-releases/seneca-biopharma-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-bid-price-rule-301192784.html
SOURCE Seneca Biopharma, Inc.
FAQ
What extension has Seneca Biopharma received from Nasdaq?
What is the new deadline for Seneca Biopharma to meet Nasdaq's bid price requirement?
What will happen if Seneca Biopharma does not meet the bid price requirement?
What is the minimum bid price requirement for Seneca Biopharma?
How can Seneca Biopharma cure the compliance deficiency?
